Industry stakeholders have made significant investments towards the development of orally administered protein and peptide therapeutics

Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics.

 

Considering the therapeutic advantages associated with proteins and peptides, this field has witnessed significant activity; researchers are actively evaluating orally bioavailable interventions. However, owing to their inherently complex structure and comparatively low stability (in in vivo conditions), proteins / peptides are predominantly administered parenterally. Recent strides in drug delivery solutions have enabled scientists to successfully explore and exploit alternative routes of drug delivery, such as transdermal, intranasal, pulmonary and oral, for protein / peptide-based therapeutics. Of these, the oral route of delivery is considered to be the most patient-friendly. This has led several companies to invest in the development of orally administered biologics. The delivery of proteins and peptides utilizes the following routes of administration. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions   has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. 

 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/192/request-sample.html

 

 

Although studies have reported that over XX oral drug delivery technologies have been designed so far, our research indicates that only XX% of the aforementioned technologies are currently being used to develop therapeutic proteins / peptides. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral proteins / peptide therapeutics market is anticipated to witness significant growth in the coming future.

 

 

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/oral-proteins-and-peptides-market/192.html  or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

  1. Targeted protein degradation market, 2022-2035
  2. Cell Therapy Manufacturing Market, 2021-2030
  3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

                       

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

 

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Publicado en Health en septiembre 07 at 01:45
Comentarios (0)
No login
Inicie sesión o regístrese para enviar su comentario
Cookies on De Gente Vakana.
This site uses cookies to store your information on your computer.